"disclosureId"|"disclosureNumber"|"title"|"statusId"|"status"|"submitterId"|"submitterFullName"|"submitterLastName"|"submitterFirstName"|"authorId"|"authorName"|"authorLastName"|"authorFirstName"|"journalId"|"congressId"|"targetName"|"targetType"|"citation"|"routingRules"|"location"|"dvDocumentNumber"|"requestTypeId"|"requestType"|"typeId"|"docType"|"type"|"otherTypeString"|"therapeuticAreaId"|"projectId"|"project"|"countryId"|"country"|"notes"|"adminNotes"|"dvDrugId"|"drug"|"studyList"|"studyNotFoundText"|"relatedDisclosureList"|"relatedRecordNotInSystemInd"|"relatedRecordNotInSystemString"|"patientInAttendYesNo"|"patAttend"|"presentationOrganizedYesNo"|"presOrganized"|"presentationOrganizedIfYes"|"originalId"|"originalResub"|"originalEncore"|"originalEncoreResub"|"regionId"|"description"|"region"|"medAffairsYesNo"|"medAffairsYesNoDesc"|"affiliatedDocumentId"|"affiliatedDocument"|"informationRelatedId"|"informationRelated"|"DocAuthoredBiomarinDataYesNo"|"docAuthorData"|"DocAuthoredBiomarinProductYesNo"|"docAuthorProd"|"submittingFunctionId"|"subFunction"|"expeditedRequestYesNo"|"expediteRequest"|"expeditedRequestJustificationString"|"authorsString"|"workflowType"|"authorBiomarinEmployeeYesNo"|"authorBioEmployee"|"externalHCAuthorYesNo"|"externalHCAuthorYesNoDesc"|"relateRecNoSysInd"|"relateRecNoSysId"|"escalationInd"|"escalationYesNo"|"escalationYesNoId"|"overdueYesNo"|"overdueYesNoId"|"submissionDate"|"decisionDate"|"disclosureDate"|"releaseDate"|"actualPubPresDate"|"plannedPubPresDate"|"closedDate"|"ReviewDays"|"DecisionDays"|"ReconcileDays"|"TotalDays"
"108"|"CLR-000108"|"Pegvaliase Phase 3 Immunogenicity Profile"|"35"|"Pending Document Upload"|"1818"|"Batroff, Simin"|"Batroff"|"Simin"|"1507"|"Lau, Kelly"|"Lau"|"Kelly"|"81"|""|"Journal of Immunology"|"journal"|""|"A1_A2"|""|"PKU-2017-MAN-006222"|"1"|""|"7"|"Manuscript"|"Manuscript"|""|""|"7"|"Pegvaliase/BMN 165/PKU"|""|""|"Previous title: Immunogenicity (how it impacts dosing and titration) 
Describe maturation of ant-PAL and anti-PEG responses; educate treating physicians
Major factor impacting dosing and time to efficacy is/"immune response/"

/"Phase 3/" only

Legacy Source Value:  Other"|""|"8"|"Phenylketonuria(PKU)"|"165-301"|""|""|"N"|""|""|""|""|""|""|"1"|"Original"|"Original"|"Original"|"4"|"North America"|"North America"|"2"|"No"|""|""|"1"|"Product in Development"|""|""|""|""|"10"|"Pharmacological Sciences"|"2"|"No"|""|"Schweighardt B, Gupta S, Lau K."|"WF_A1_A2A1"|"1"|"Yes"|"2"|"No"|"No"|"2"|"N"|"No"|"2"|"No"|"2"|"05/08/2017"|""|""|"02/21/2018"|""|"05/23/2018"|""|""|"1"|""|""
